MOTS is a mitochondrial-derived peptide that activates AMPK, shares signalling pathways with exercise and declines with age in the models studied. This overview covers its origin, mechanism, the main areas of research and what to consider when working with it in the laboratory.
For decades the textbook view of mitochondria was straightforward: these organelles convert nutrients into ATP through oxidative phosphorylation, and their small circular genome encodes only the 13 proteins needed for the electron transport chain plus the ribosomal and transfer RNAs required to translate them.
That understanding changed with the discovery of mitochondrial-derived peptides (MDPs). Mitochondrial DNA contains previously unrecognised small open reading frames (sORFs) that encode bioactive peptides. These peptides are produced, secreted and function as signalling molecules, giving mitochondria a voice in cellular decision-making.
MOTS (mitochondrial open reading frame of the 12S rRNA type-c) was identified in 2015 from the 12S rRNA gene of mitochondrial DNA. It is a 16-amino-acid peptide (sequence MRWQEMGYIFYPRKLR). Unlike hormones produced by dedicated endocrine glands, MOTS is produced by mitochondria across multiple tissue types and has been detected both within tissues and in circulation, which suggests both local and systemic signalling roles.
Key point: MOTS represents retrograde signalling, communication from mitochondria back to the nucleus. Under metabolic stress, MOTS translocates to the cell nucleus, where it regulates the expression of nuclear genes, creating a direct information pathway between the two genomes in every cell.
This retrograde capacity positions MOTS as more than a metabolic regulator. It is a messenger that lets mitochondria inform the nucleus about cellular energy status and trigger adaptive transcriptional responses, a different communication paradigm from the well-studied anterograde signalling (nucleus to mitochondria) that governs mitochondrial biogenesis.
The best-characterised molecular effect of MOTS is activation of AMP-activated protein kinase (AMPK), the cell's master energy sensor. AMPK monitors the AMP:ATP ratio and switches on catabolic pathways when energy is depleted.
MOTS activates AMPK through a specific mechanism. The peptide inhibits the folate cycle, which is essential for de novo purine biosynthesis. Disrupting this pathway leads to accumulation of 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), an endogenous intermediate that is a well-known AMPK activator.
The indirect route matters: MOTS engages AMPK through the same metabolic-sensing pathway the cell uses endogenously rather than through direct pharmacological binding, so the resulting activation is integrated with the cell's actual metabolic state.
Once AMPK is activated, it triggers a broad cascade of metabolic adjustments described across the AMPK literature:
This multi-arm reprogramming is why MOTS shows broad effects in research models: rather than toggling one pathway, it shifts the metabolic orientation of the cell toward catabolism and energy conservation.
MOTS is studied across several interconnected areas of metabolic research, each drawing on different aspects of its AMPK-mediated and AMPK-independent signalling.
Work in cell culture and rodent models has examined MOTS in glucose handling at several levels: cellular glucose uptake, insulin-sensitivity markers and hepatic glucose output. The reported effects involve both AMPK-dependent mechanisms (GLUT4 translocation) and AMPK-independent pathways that are still being characterised.
Because glucose homeostasis is central to so many physiological processes, this remains one of the most active areas of MOTS research.
Through AMPK-mediated inhibition of ACC and its downstream effects on fatty acid oxidation, MOTS research has reported effects on lipid metabolism in several tissue types. In hepatic models, MOTS exposure has been associated with reduced lipid accumulation and higher fatty acid oxidation rates; in adipose models it has been associated with changes in lipid storage and mobilisation dynamics.
One of the most discussed observations is that endogenous MOTS levels decline with age in the tissues studied. The decline parallels the well-documented deterioration of mitochondrial function during ageing and correlates with age-related decreases in metabolic efficiency, insulin sensitivity and exercise capacity in the models examined.
Whether the decline contributes to metabolic deterioration or is only a biomarker of mitochondrial ageing is an open question, and the distinction matters for how the molecular mechanisms of metabolic ageing are understood.
Under metabolic stress such as glucose deprivation or oxidative stress, MOTS translocates to the nucleus and regulates the expression of genes involved in antioxidant defence and metabolic adaptation. This positions the peptide as a stress-responsive signal that activates protective transcriptional programmes when cells face metabolic challenge.
The relationship between MOTS and exercise physiology is one of the most actively investigated areas.
Studies in rodents and in human exercise studies have shown that circulating MOTS levels increase in response to acute exercise. This exercise-responsive release suggests MOTS functions as an "exerkine", a signalling molecule released during physical activity that mediates part of the metabolic response to exercise.
The magnitude of release appears to track exercise intensity, and the post-exercise elevation persists for several hours, a temporal pattern consistent with a signalling role in the adaptive metabolic response to activity.
Exogenous MOTS in research models activates many of the same metabolic pathways that exercise activates: AMPK activation, PGC-1α upregulation, glucose uptake and fatty acid oxidation. This overlap is why the literature describes MOTS as having "exercise-mimetic" properties.
Research context: the exercise-mimetic label refers to shared pathway activation, not to a claim that MOTS reproduces the physiological effects of exercise. Exercise produces mechanical, cardiovascular and neurological adaptations that a single peptide cannot; the overlap is specifically in AMPK-mediated metabolic signalling.
Preclinical studies have examined MOTS against performance-related metrics such as running endurance, skeletal-muscle metabolism and recovery from metabolic stress. In aged mouse models, exogenous MOTS has been associated with changes in these metrics, which is the basis for the hypothesis that age-related decline in endogenous MOTS contributes to reduced exercise capacity.
Identity and purity. As with any research peptide, experimental reliability depends on the material: a batch-specific Certificate of Analysis documenting HPLC purity and mass-spectrometry identity confirmation, so that impurities or degradation products do not become confounding variables. See our certificates of analysis.
Storage and handling. Lyophilised peptide is kept frozen and protected from light and moisture. Once reconstituted, solutions are aliquoted to avoid repeated freeze-thaw cycles. Our storage guide and reconstitution guide cover the general laboratory practice.
MOTS is a 16-amino-acid peptide encoded within the mitochondrial genome, in a small open reading frame of the 12S rRNA gene. It belongs to the class of mitochondrial-derived peptides (MDPs) and is studied for its role in metabolic signalling, AMPK pathway activation and communication between the mitochondrial and nuclear genomes.
Mitochondrial peptide signalling is the process by which small peptides encoded in mitochondrial DNA act as signalling molecules that regulate cellular metabolism. These mitochondrial-derived peptides represent retrograde signalling, communication from the mitochondria back to the nucleus and other cellular compartments. MOTS is one of the most studied of them.
In the published mechanism, MOTS inhibits the folate cycle and de novo purine biosynthesis, which leads to accumulation of AICAR, an endogenous AMPK activator. AMPK is therefore engaged through the cell's own metabolic-sensing route rather than by direct pharmacological binding.
Research describes overlap between the metabolic pathways activated by MOTS and those activated by exercise: endogenous MOTS levels rise during physical activity, and exogenous MOTS in research models activates several of the same AMPK-dependent pathways. The term refers to shared pathway activation, not to a claim that the peptide reproduces the physiology of exercise.
Explore our catalog of research-grade peptides with certificates of analysis.
MOTS Research Peptide Browse ProductsDisclaimer: This compound is intended for laboratory research use only. It is not approved for human or veterinary use by the FDA or any regulatory agency. The findings described are from the cited cell-culture, rodent and exercise-physiology studies. Nothing in this article is medical advice, and it does not describe or recommend any use, administration or dosing of this compound.